for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

PMV Pharmaceuticals Inc

PMVP.OQ

Latest Trade

37.63USD

Change

1.44(+3.98%)

Volume

22,101

Today's Range

36.71

 - 

39.30

52 Week Range

31.06

 - 

62.41

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
36.19
Open
36.78
Volume
22,101
3M AVG Volume
3.35
Today's High
39.30
Today's Low
36.71
52 Week High
62.41
52 Week Low
31.06
Shares Out (MIL)
44.77
Market Cap (MIL)
1,620.36
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Pmv Pharmaceuticals Reports QTRLY Loss Per Share $1.46

PMV Pharmaceuticals Inc Shares Open 94.4% Above IPO Price In Debut On Nasdaq

PMV Pharma Announces Pricing Of Initial Public Offering

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About PMV Pharmaceuticals Inc

PMV Pharmaceuticals, Inc. is a precision oncology company. The Company is focused on discovering and developing small molecule, tumor-agnostic therapies targeting p53 mutations. It’s lead product candidate, PC14586, is designed to potently and selectively correct p53 misfolding caused by a specific p53 mutation, Y220C, while sparing wild-type p53. It is also using its precision oncology platform to develop a pipeline of oral small molecule product candidates that structurally correct other p53 hotspot mutations to restore their wild-type function. Its second program, R273H, targets the p53 R273H hotspot mutation.

Industry

Biotechnology & Drugs

Contact Info

8 Clarke Drive

CRANBURY, NJ

08512

United States

+1.609.6426664

http://pmvpharma.com/

Executive Leadership

David H. Mack

President, Chief Executive Officer, Co-Founder, Director

Winston Kung

Chief Financial Officer, Chief Operating Officer

Deepika Jalota

Senior Vice President - Head of Regulatory Affairs

Thomas Davis

Vice President - Biology

Binh Vu

Vice President - Chemistry

Key Stats

2.00 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2020(E)

0.0K
EPS (USD)

2020(E)

-2.058
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
4.39
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up